Abstract: A Pickering particle dry powder and a preparation method are used in food processing. The preparation method includes stirring peanut protein isolate and water as raw materials to obtain peanut protein isolate dispersion, subjecting the peanut protein isolate dispersion to ultrasonic treatment, subjecting the resultant to cross-linking reaction with transglutaminase to obtain a monolithic geld, shearing and homogenizing the monolithic gel to obtain a microgel particle dispersion, spray drying the microgel particle dispersion to obtain the Pickering particle dry powder. The Pickering particle dry powder prepared by the ultrasonic-assisted enzyme method is still in nanometer level after rehydration, which is beneficial to preparing Pickering emulsion with strong stability. The preparation method has the advantages of simple operation and low cost, which is beneficial to actual production in the food industry.

Abstract: Provided are a fibroblast activation protein inhibitor (FAPI) dimer compound, an FAPI dimer-based positron emission tomography (PET) imaging agent for tumor diagnosis, and a preparation method and use thereof. An amphiphilic polyethylene glycol (PEG) chain and a dimerized structure of FAPI in the FAPI dimer compound with a structure shown in formula I can improve the in vivo kinetic properties of the compound and prolong a residence time of the compound in a tumor, thereby improving the uptake and imaging effects in the tumor. The accurate tumor diagnosis can be achieved by labeling the FAPI dimer compound with a diagnostic nuclide (68Ga), which has promising application prospects in PET imaging for diagnosis and in the preparation of a therapeutic nuclide (such as 177Lu or 90Y)-labeled drug for treating a FAP-?-expressing tumor.

Abstract: A CO2 gas-liquid phase transition-based multistage compression energy storage apparatus for converting thermal energy into mechanical energy, including: a gas storage; a liquid storage tank; an energy storage assembly, which includes compressors and energy storage heat exchangers; an energy release assembly (400), which includes energy release heat exchangers and expanders; a heat exchange assembly the energy generated by the energy storage assembly, and the energy release heat exchangers being capable of receiving the energy temporarily stored by the heat exchange assembly; and a driving assembly, which includes an energy input member and a first driving member, the energy input member absorbing external thermal energy to drive the first driving member to work, and the first driving member being used for driving the compressors to work.

Abstract: Disclosed are an online analysis system and method for a line loss of a transmission line. The system includes: a terminal extension and a terminal host, where time information synchronization between the terminal extension and the terminal host and between terminal extensions is performed by a clock synchronization module, and communication between the terminal extension and the terminal host and between the terminal extensions is performed by a communications module; and a line loss management platform, configured to receive measurement data of the terminal extension and the terminal host, match time information in the measurement data, and if time information in the measurement data of the terminal extension and the terminal host is matched, and time information in measurement data of the terminal extensions is matched, determine corresponding line loss information based on corresponding measurement information.

Abstract: Disclosed are an online analysis system and method for a line loss of a transmission line. The system includes: a terminal extension and a terminal host, where time information synchronization between the terminal extension and the terminal host and between terminal extensions is performed by a clock synchronization module, and communication between the terminal extension and the terminal host and between the terminal extensions is performed by a communications module; and a line loss management platform, configured to receive measurement data of the terminal extension and the terminal host, match time information in the measurement data, and if time information in the measurement data of the terminal extension and the terminal host is matched, and time information in measurement data of the terminal extensions is matched, determine corresponding line loss information based on corresponding measurement information.

Abstract: A peanut stem and leaf extract contains at least naringenin-4,7?-dimethyl ether, 2?-O-methylisoliquiritigenin, linalool and ferulic acid. The peanut stem and leaf extract can be prepared by pulverizing dried peanut stems and leaves to a micropowder level, followed by water extraction. The water extraction includes placing the pulverized peanut stems and leaves in water at a temperature of 75 to 85° C. for 4 to 5 hours. The preparation method can efficiently extract active substances in peanut stems and leaves, and the peanut stem and leaf extract can effectively improve sleep and treat insomnia.

Abstract: An optical fiber array device includes a substrate, a cover plate, and a ceramic ferrule array. A receiving groove is defined in one surface of the substrate. The substrate and the cover plate are coupled together and cover the receiving groove. The receiving groove includes a first groove wall and a second groove wall. The ceramic ferrule array includes at least one layer of ceramic ferrules and a number of positioning members. Opposite sides of the at least one layer of ceramic ferrules respectively abut the first groove wall and the second groove wall. Each of the positioning members is located between two adjacent ceramic ferrules.

Abstract: A pure peanut butter is prepared by compounded peanut varieties. The raw material of the pure peanut butter includes: 50 to 90 parts of high oleic peanuts and 10 to 50 parts of high sugar peanuts. The preparation method is as follows: high oleic peanuts and high sugar peanuts are respectively baked, the baking conditions for the high oleic peanuts are as follows: a baking temperature of 140 to 180° C., and a baking time of 15 to 35 minutes; the baking conditions for the high sugar peanuts are as follows: a baking temperature of 130 to 160° C., and a baking time of 10 to 30 minutes; and the baked high oleic peanuts and high sugar peanuts are subjected to ventilation and cooling, and after removal of peanut skin, mixed and then subjected to coarse grinding and fine grinding.

Abstract: A light-emitting device includes a package structure and a light-emitting chip. The package structure has a light exiting surface, a rear surface facing away from the light exiting surface, a groove inward recessed on the rear surface, and an outer surrounding side wall surrounding the groove. The light-emitting chip is disposed in the groove. The width of the package structure gradually decreases from the light exiting surface to the rear surface. The width of the groove gradually increases from inside to outside of the groove.

Abstract: An LED structure includes a substrate, an LED chip disposed on the substrate, a wavelength conversion layer disposed above a light-emitting surface of the LED chip, and a cut-on optical filter disposed on a central region of the wavelength conversion layer.

Abstract: A light-emitting device includes a package structure and a light-emitting chip. The package structure has a light exiting surface, a rear surface facing away from the light exiting surface, a groove inward recessed on the rear surface, and an outer surrounding side wall surrounding the groove. The light-emitting chip is disposed in the groove. The width of the package structure gradually decreases from the light exiting surface to the rear surface. The width of the groove gradually increases from inside to outside of the groove.

Abstract: An LED structure includes a substrate, an LED chip disposed on the substrate, a wavelength conversion layer disposed above a light-emitting surface of the LED chip, and a cut-on optical filter disposed on a central region of the wavelength conversion layer.

Abstract: 5-Membered heterocyclic amides and related compounds are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

Abstract: 5-Membered heterocyclic amides and related compounds are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

Abstract: Heteroaryl amide analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

Abstract: Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds analogues of the formula: wherein R, R2, R5, E, Z1, Z3, Z4, and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds of the invention bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds, which are useful as probes for the localization of C5a receptors.

Abstract: Heteroaryl amide analogues are provided, of Formula (I), wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

Abstract: A decoding method for biphase-encoded data is provided. The decoding method includes detecting falling-edge transitions in the biphase-encoded data to decode according to a time difference (?t) between each two adjacent falling-edge transitions and the logic value of previous bit. When ?t is 1 bit period and previous bit is logic 1, it's determined that present bit is logic 1. When ?t is 1 bit period and previous bit is logic 0, it's determined that present bit is logic 0. When ?t is 1.5 bit periods and previous bit is logic 1, it's determined that present and next bits are both logic 0. When ?t is 1.5 bit periods and previous bit is logic 0, it's determined that present bit is logic 1. When ?t is 2 bit periods and previous bit is logic 1, it's determined that present and next bits are logic 0 and 1 respectively.

Abstract: 4,5-disubstituted-2-arypyrimidines of Formula I and Formula II are provided: wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I and II bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 4,5-disubstituted-2-arylpyrimidines, which are useful as probes for the localization of C5a receptors.